Direct oral anticoagulants and travel-related venous thromboembolism
Travel- related thromboembolism reflects the relationship between venous thromboembolism (VTE) and long-haul flights. Although this condition is rare, it may cause significant morbidity and mortality. Therefore, travelers should be evaluated for the risks for thrombosis. Travel physicians should emp...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2018-11-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2018-0085 |
| _version_ | 1818738319416098816 |
|---|---|
| author | Chamnanchanunt Supat Rojnuckarin Ponlapat |
| author_facet | Chamnanchanunt Supat Rojnuckarin Ponlapat |
| author_sort | Chamnanchanunt Supat |
| collection | DOAJ |
| description | Travel- related thromboembolism reflects the relationship between venous thromboembolism (VTE) and long-haul flights. Although this condition is rare, it may cause significant morbidity and mortality. Therefore, travelers should be evaluated for the risks for thrombosis. Travel physicians should employ a clinical risk score and select in vestigations, prophylaxis, and treatment that are appropriate for each individual. This review summarizes current VTE clinical risk scores and patient management from various reliable guidelines. We summarized 16 reliable publications for reviewing data. Direct oral anticoagulants (DOACs) are currently the standard treatment for VTE and a prophylactic measure for VTE in orthopedic surgery. Compared with a vitamin K antagonist (VKA), DOACs show better safety and similar efficacy without the need for monitoring, and have fewer food/drug interactions. Inferred from the data on general VTE, DOACs may be used to treat travel-related VTE. Although the data are lacking, DOACs may be used off-label as VTE prophylax is. Before using DOACs, physicians must know the pharmacology of the drugs well and should realize that the availability of antidotes for bleeding complications is limited. |
| first_indexed | 2024-12-18T01:07:03Z |
| format | Article |
| id | doaj.art-dc88c7a649ed4035b2d1487940212597 |
| institution | Directory Open Access Journal |
| issn | 2391-5463 |
| language | English |
| last_indexed | 2024-12-18T01:07:03Z |
| publishDate | 2018-11-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Medicine |
| spelling | doaj.art-dc88c7a649ed4035b2d14879402125972022-12-21T21:26:12ZengDe GruyterOpen Medicine2391-54632018-11-0113157558210.1515/med-2018-0085med-2018-0085Direct oral anticoagulants and travel-related venous thromboembolismChamnanchanunt Supat0Rojnuckarin Ponlapat1Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, 10400Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Ext 80252, ThailandTravel- related thromboembolism reflects the relationship between venous thromboembolism (VTE) and long-haul flights. Although this condition is rare, it may cause significant morbidity and mortality. Therefore, travelers should be evaluated for the risks for thrombosis. Travel physicians should employ a clinical risk score and select in vestigations, prophylaxis, and treatment that are appropriate for each individual. This review summarizes current VTE clinical risk scores and patient management from various reliable guidelines. We summarized 16 reliable publications for reviewing data. Direct oral anticoagulants (DOACs) are currently the standard treatment for VTE and a prophylactic measure for VTE in orthopedic surgery. Compared with a vitamin K antagonist (VKA), DOACs show better safety and similar efficacy without the need for monitoring, and have fewer food/drug interactions. Inferred from the data on general VTE, DOACs may be used to treat travel-related VTE. Although the data are lacking, DOACs may be used off-label as VTE prophylax is. Before using DOACs, physicians must know the pharmacology of the drugs well and should realize that the availability of antidotes for bleeding complications is limited.https://doi.org/10.1515/med-2018-0085apixabandabigatranedoxabanrivaroxabanvenous thromboembolismaviation medicinetravel-related illness |
| spellingShingle | Chamnanchanunt Supat Rojnuckarin Ponlapat Direct oral anticoagulants and travel-related venous thromboembolism Open Medicine apixaban dabigatran edoxaban rivaroxaban venous thromboembolism aviation medicine travel-related illness |
| title | Direct oral anticoagulants and travel-related venous thromboembolism |
| title_full | Direct oral anticoagulants and travel-related venous thromboembolism |
| title_fullStr | Direct oral anticoagulants and travel-related venous thromboembolism |
| title_full_unstemmed | Direct oral anticoagulants and travel-related venous thromboembolism |
| title_short | Direct oral anticoagulants and travel-related venous thromboembolism |
| title_sort | direct oral anticoagulants and travel related venous thromboembolism |
| topic | apixaban dabigatran edoxaban rivaroxaban venous thromboembolism aviation medicine travel-related illness |
| url | https://doi.org/10.1515/med-2018-0085 |
| work_keys_str_mv | AT chamnanchanuntsupat directoralanticoagulantsandtravelrelatedvenousthromboembolism AT rojnuckarinponlapat directoralanticoagulantsandtravelrelatedvenousthromboembolism |